Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014 Nov 29; 15:469.

View in: PubMed

subject areas

Antineoplastic Agents
Carcinoma, Squamous Cell
Chemoradiotherapy
Chemotherapy, Adjuvant
Clinical Protocols
Disease-Free Survival
Double-Blind Method
ErbB Receptors
Head and Neck Neoplasms
Humans
Molecular Targeted Therapy
Neoplasm Recurrence, Local
Neoplasm Staging
Protein Kinase Inhibitors
Quality of Life
Quinazolines
Research Design
Risk Factors
Time Factors
Treatment Outcome

authors with profiles

Ezra Cohen